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Summary
Background.— Alcohol septal ablation (ASA) is a therapeutic catheter-based option and an
alternative to surgical myectomy in the treatment of patients with hypertrophic obstructivecardiomyopathy; cardiomyopathy. Although the safety of the ASA procedure has been consistently improved, a
Interventional
cardiology;
Alcohol septal
ablation
temporary transvenous pacemaker is recommended for at least 48 h postprocedure, with sev-
eral drawbacks, including the risk of cardiac perforation and infection, and the absence of any
ﬁxation mechanism. In addition, femoral artery catheterization has resulted in a concomitant
increase in bleedings and iatrogenic femoral artery injuries.
Abbreviations: ASA, alcohol septal ablation; AV, atrioventricular; BBB, bundle branch block; HOCM, hypertrophic obstructive
cardiomyopathy.
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Temporary pacing Aims.— To evaluate and validate the feasibility of less invasive management of ASA using the
transradial approach and a subclavian wired temporary pacemaker.
Methods.— To avoid transfemoral temporary pacing, we used a subclavian bipolar active-
ﬁxation permanent pacing lead, stitched to the skin and connected to a desterilized
recuperation pacemaker. The day before discharge, if there was no high-degree atrioventricular
block, the pacemaker lead was removed. In all patients, we used the right radial access and
the left main was cannulated with a 6F Judkins left 3.5 guiding catheter.
Results.— Thirty consecutive patients were prospectively and successfully included in our study.
No complication was observed during the hospital stay, neither access-site nor stimulation-lead
related.
Conclusions.— Our study shows the feasibility and safety of a transradial approach and a sub-
clavian wired temporary pacemaker. The reduction in periprocedural complications offered by
this strategy reﬂects the less invasive nature of ASA, without increasing the cost and complexity
of the procedure.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé
Contexte.— L’alcoolisation septale est une alternative à la chirurgie dans la prise en charge
des cardiomyopathies hypertrophiques obstructives. Malgré l’amélioration de la sécurité de
cette technique percutanée, le risque de trouble conductif nécessite une stimulation externe
pour au moins 48 heures après la procédure. La technique habituelle de stimulation temporaire
transfémorale expose à un risque de tamponnade, de déplacement de sonde ou d’infection. De
plus, la voie d’abord artérielle fémorale qui est utilisée dans toutes les études majore le risque
hémorragique de la procédure.
Objectifs.— Notre objectif est d’évaluer la faisabilité et l’intérêt d’un abord artériel radial
associé à une stimulation temporaire par sonde vissée sous-clavière pour réduire le risque de
complication périprocédurale.
Méthodes.— Nous avons utilisé des sondes de stimulation bipolaires vissées introduites par voie
sous-clavière, la partie proximale de la sonde restant externe et connectée à un boîtier de
pacemaker de récupération programmé en VVI. La veille de la sortie, en l’absence de trouble
conductif, le dispositif était retiré. La voie artérielle radiale a été également proposée à tous
les malades, avec utilisation de cathéter guide JL 3.5 6F.
Résultats.— Trente patients consécutifs ont pu bénéﬁcier avec succès de cette approche.
Nous n’avons observé durant la phase hospitalière aucune complication liée à la stimulation
temporaire ou à la voie d’accès artérielle.
Conclusions.— Notre étude montre la faisabilité et l’intérêt en terme de sécurité de
l’abord radial et de la stimulation temporaire sous-clavière par sonde vissée. La réduction
des complications et l’amélioration du confort du patient s’inscrivent dans la logique du
développement de l’alcoolisation septale, sans majoration du coût ou de la complexité de la
procédure.
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Background
ASA is a therapeutic catheter-based option and an alter-
native to surgical myectomy in the treatment of patients
with HOCM [1,2]. Both techniques currently appear to pro-
vide equivalent results in mortality, and in subjective and
objective measurements of performance in symptomatic
HOCM patients [3—5]. The total number of ASAs performed
largely outnumbers surgical septal reduction. However, the
procedural complication rate probably still exceeds that
of myectomy, especially related to AV conduction prob-
lems [3], transient pacing and femoral access site. The
safety of the ASA procedure has been consistently improved,
using myocardial contrast echocardiography to improve
localization of the targeted septal branch, with smaller vol-
a
o
ts droits réservés.
mes of alcohol injected at a slower rate [6—8]. Onset
f delayed complete heart block may occur up to several
ays after an uncomplicated ASA procedure [9,10]. There-
ore, a temporary transvenous pacemaker is recommended
or at least 48 hours postprocedure, and telemetric mon-
toring for 5 to 8 days is recommended by some groups
9]. Transfemoral temporary pacing catheters have several
rawbacks, including the risk of cardiac perforation and
nfection, and the absence of any ﬁxation mechanism. In
ddition, femoral artery catheterization has resulted in a
oncomitant increase in bleedings and iatrogenic femoral
rtery injuries. The aim of the present study was to evalu-
te and validate the feasibility of less invasive management
f ASA using the transradial approach and a subclavian wired
emporary pacemaker.
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Figure 1. Chest radiography showing the position of the pacing
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sead. The active-ﬁxation screwed mechanism is visible, connected
o a reusable generator secured to the skin with a large occlusive
ressing to maintain sterility (insert).
ethods
atients
onsecutive patients with symptomatic HOCM despite
ptimal medical treatment (New York Heart Association
unctional class III to IV) were prospectively included in our
tudy. All subjects demonstrated a dynamic left ventricu-
ar outﬂow tract gradient of at least 50mmHg at rest or on
rovocation and a septal thickness > 18mm. Patients with a
egative Allen’s test or speciﬁc contraindication for radial
ccess were excluded. Our institutional review committee
pproved the study and all patients gave written informed
onsent.ubclavian external temporary pacing
o avoid transfemoral temporary pacing, we performed a
afer approach the day before ASA. Using a subclavian 7Fr
c
a
i
igure 2. (A) Radial access and left anterior descending coronary art
arrow). (B) Inﬂation of the balloon catheter in the proximal part of the
tump (arrow) of the occluded septal branch. Generator and active-ﬁxatT. Cuisset et al.
eel-away introducer sheath, a bipolar active-ﬁxation per-
anent pacing lead was positioned in the right ventricle
nder ﬂuoroscopy guidance, with the tip screwed into the
pical septum (Fig. 1). Taking into account the potential
omplications of subclavian way (infection, haemopneu-
othorax and bleeding), lead insertion was performed only
y skilled personnel, under stringent aseptic technique in
he electrophysiology lab. The lead was stitched to the skin
sing the anchoring sleeve, then connected to a VVI perma-
ent pacemaker that had been preprogrammed in bipolar
ode for stimulation and detection (rate 60 beats/minute,
utput 5 V). This was secured to the skin with an occlu-
ive sticking (Fig. 1). We used a desterilized recuperation
acemaker for cost-effectiveness.
ercutaneous transluminal septal myocardial
blation
n all patients, we used right radial access and the left main
as cannulated with a 6F Judkins left 3.5 guiding catheter.
fter identiﬁcation of the septal branches of the left ante-
ior descending coronary artery, a 1.5—2.5× 10mm balloon
as introduced over a 0.014 inch guidewire and positioned
nto the ﬁrst septal branch. If the position of the balloon
as considered satisfactory, the guidewire was removed and
he balloon inﬂated. Subsequently, 1mL of echocontrast
gent (Levovist, Schering AG, Berlin, Germany) was injected
hrough the balloon catheter shaft. With echocardiography,
he myocardial territory supplied by this septal branch was
dentiﬁed and retrograde spill of contrast into the left ante-
ior descending coronary artery or the right ventricle was
xcluded. If satisfying images were obtained, 1mL of con-
entrated ethanol (at a rate of 0.5mL/30 sec) was injected
hrough the balloon catheter shaft under close echocardio-
ram surveillance. After 5min, the balloon was deﬂated
nd coronary angiography was repeated to conﬁrm septal
cclusion and the integrity of the left anterior descend-
ng coronary artery (Fig. 2). A second perforator artery was
annulated and ablated if gradient reduction < 50% was not
chieved after the ﬁrst septal ablation.
After the procedure, patients were observed for 2 days
n the intensive care unit and 6 days on the cardiology ward.
ery visualization before therapy, showing large ﬁrst septal branch
septal branch was determined. (C) Final visualization of the vessel
ion screwed lead are visible.
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Radial access and our original temporary pacing method
allowed rapid ambulation. The day before discharge, if
there was no high-degree AV block, the pacemaker lead was
removed.
Statistical analysis
Statistical analysis was performed using Graphpad Prism
software (version 4.00; Graphpad Software, Inc., San
Diego, CA, USA). Continuous variables are expressed as
means± standard deviations and categorical variables as
frequencies and percentages.
Results
Thirty consecutive patients were prospectively included in
our study. Among the 30 patients who underwent ASA, the
mean age was 64.6 years and 68% were women. The baseline
characteristics are presented in Table 1. All of the proce-
dures were successful, with radial access and subclavian
Table 1 Patient characteristics (n = 30).
Women (%) 68
Age at procedure (years) 65 ± 14
BMI 29 ± 3
Resting systolic blood pressure (mmHg) 127 ± 9
Family history of HOCM (%) 57
Family history of sudden death caused (%) 29
Symptoms
Dyspnoea NYHA class 3.1 ± 0.2
Angina (%) 22
Palpitations (%) 57
Presyncope-syncope (%) 43
BNP (pg/mL) 811 ± 250
Medications at procedure
Beta-blocker (%) 86
ACE inhibitor (%) 21
Calcium channel blocker (%) 36
Amiodarone (%) 7
Oral anticoagulation (%) 21
Aspirin (%) 21
Preprocedure heart rhythm
QRS (ms) 98 ± 10
Left bundle branch block (%) 7
Normal sinus rhythm (%) 100
Preprocedural echocardiogram
LVOT gradient at rest, G(max) (mmHg) 89 ± 40
Septal thickness (mm) 22 ± 6
Pulmonary artery mean pressure (mmHg) 35 ± 12
Left ventricular ejection fraction (%) 70 ± 4
Values are mean± standard deviation for quantitative variables
and n (%) for qualitative variables. ACE: angiotensin-converting
enzyme; BMI: body mass index; BNP: brain-type natriuretic
peptide; HOCM: hypertrophic obstructive cardiomyopathy;
LVOT: left ventricular outﬂow tract; NYHA: New York Heart
Association.
Table 2 Procedural results (n = 30).
Number of septal arteries injected 1 ± 0.5
Volume of ethanol injected (mL) 1.2 ± 0.3
Change in LVOT gradient (mmHg)
Baseline 84 ± 29
Postablation 19 ± 16
Troponin peak (ng/mL) 53 ± 24
QRS (ms) 119 ± 24
Complications
Right bundle branch block postablation (%) 50
New permanent pacemaker dependency (%)13
Values are mean± standard deviation for quantitative variables
and n (%) for qualitative variables. LVOT: left ventricular outﬂow
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emporary pacing using an active-ﬁxation lead. The average
radient was 84.2± 29.4mmHg at the start of the proce-
ure and 18.7± 16mmHg at its completion. Overall, 12 of
0 patients (40%) developed right BBB, none developed left
BB and six (20%) developed complete AV block, requiring
permanent pacemaker implantation in four cases (13.3%).
ithout our approach allowing safer and prolonged tempo-
ary pacing, the other two patients would probably have
ad deﬁnitive implantation for a ﬁnally transient AV block.
atients who experienced deﬁnitive complete AV block dif-
ered from patients without complete heart block in terms
f QRS duration (116ms vs 95ms) and pre-existing left BBB
50% vs 8%). Sex, age and amount of ethanol were not differ-
nt in these subgroups. No complication was observed during
he hospital stay, neither access-site nor stimulation-lead
elated (Table 2). At 6-month follow-up, all of the patients
ho underwent implantation of a permanent pacemaker
emained pacemaker dependent.
iscussion
he results of the present study suggest the validation of
potentially safer way to conduct ASA in patients with
OCM, reducing complications and the need for perma-
ent pacemaker implantation. Over a number of decades,
SA has emerged as a potentially less invasive, alternative
ode of treatment of HOCM [1,3,5]. However, the proce-
ural complication rate exceeds that of myectomy, which
emains the ‘gold standard’ therapy in centres with skilled
ardiac surgeons [11]. In-hospital complications of ASA
nclude complete AV block, tamponade, sustained ventric-
lar arrhythmias, left anterior descending coronary artery
issection, remote infarction, pulmonary embolism, stroke,
itral regurgitation, ventricular septal defects and groin
aematoma or femoral artery injuries. In-hospital mortality
anges from 0 to 4% and at experienced centres, mortality
s in a lower range even in high-risk patients [7]. No impair-
ents in short- or long-term survival were noted in recent
eta-analyses [3,5]. Our study demonstrated the feasibil-
ty and safety of less invasive management of ASA using
he transradial approach and a subclavian wired temporary
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acemaker. This option may be useful for reducing the
omplication rate of the procedure.
alue of screwed pacemaker leads
he occurrence of pacemaker dependency is not rare after
SA, even when low amounts of ethanol are used under
chocardiography guidance [3]. The pacemaker implanta-
ion rate in experienced centres remains at around 10%
9]. However, complete AV block may be a transient phe-
omenon occurring in almost 20% of cases [12], while a
ew patients might develop complete AV block up to 7 days
fter ASA [10]. Therefore, a watchful waiting strategy with
temporary pacemaker after ASA seems to be a reason-
ble approach to lower the rate of deﬁnitive implantation
nd to avoid adverse events related to delayed AV block.
atients with early or delayed complete AV block usually
eceive a permanent pacemaker. However, there is also a
igniﬁcant recovery in echocardiogram variables of cardiac
onduction with time, resulting in a low pacing require-
ent for many patients who received early permanent
acemakers [7]. These data suggest a prolonged period for
emporary pacing to avoid some unjustiﬁed implantations.
owever, several complications may occur with long-term
emporary transfemoral pacing, including tamponade, sub-
equent displacement because of the absence of any ﬁxation
echanism, infection or ventricular arrhythmias [13,14].
he requirement for transfemoral temporary pacing sup-
ort with these potential problems and prolongation of the
mmobilization of the elderly patient greatly lowers our
hreshold for an early permanent pacemaker. The use of
n active-ﬁxation electrode with an external pacemaker is
robably of value in this context. The active-ﬁxation lead
an be easily positioned by the subclavian route and con-
ected to a generator with a high output in bipolar mode,
ecured to the skin. Although myocardial perforation using
ermanent pacing leads has been reported after pacemaker
mplantation [15], this is very rare. Moreover, it allows rapid
mbulation, early discharge from the intensive care unit
nd a reduction in infection and thromboembolic risks. The
ncreased cost of the electrode is easily offset by the reduc-
ions in complications and the duration of the stay in the
ntensive care unit, and potential avoidance of proton-pump
nhibitors.
alue of radial access
he transradial approach for coronary intervention was ﬁrst
ntroduced by Kiemeneij et al. [16] and its beneﬁts have
ubsequently been clearly demonstrated in several studies
rom different centres [17]. Radial access reduced the risk of
ajor bleeding and the length of hospital stay after coronary
ntervention compared with femoral access. This reduction
n major bleeding corresponded to a trend for reduction in
schaemic events with radial access. In multiple studies,
ajor bleeding events have been shown to be indepen-
ently associated with a marked increased risk of death and
schaemic events in patients undergoing percutaneous coro-
ary intervention and those with acute coronary syndromes
18,19]. In our small population, procedural success was ele-
ated (100%) and access site bleeding complications were
irtually eliminated, even in the 21.4% patients with oralT. Cuisset et al.
nticoagulation. On top of the bleeding hazard reduction,
he transradial approach and a subclavian wired tempo-
ary pacemaker allow safe and rapid ambulation. The ability
o rapidly ambulate patients is a signiﬁcant beneﬁt of the
ransradial approach, comfortable for the patient and low-
ring the thromboembolic risk [20]. In the present study,
he length of stay in the intensive care unit and the total
ength of hospital stay were shortened with this strategy
ompared with other studies and registries of ASA in HOCM.
here is a substantial economic beneﬁt with the transradial
pproach, which can be demonstrated with either eval-
ation of hospital costs or total hospital charge [20,21].
rocedural morbidity is less and patients overwhelmingly
refer the transradial over the femoral approach.
onclusions
lthough surgical myectomy continues to be the ‘gold-
tandard’ treatment for refractory HOCM, ASA has emerged
o be an attractive alternative, offering interesting results
n terms of mortality beneﬁt and functional improvement.
n many centres, the frequency of surgical myectomy has
een largely reduced in favour of performing ASA as the
eﬁnitive treatment strategy. However, this technique car-
ies with it a certain number of speciﬁc complications—in
articular, a higher level of AV conduction problems and the
isks of the transfemoral route. Our study shows the feasi-
ility and safety of a transradial approach and a subclavian
ired temporary pacemaker. The reduction of periprocedu-
al complications offered by this strategy reﬂects the less
nvasive approach of ASA, without increasing the cost and
omplexity of the procedure.
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